Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

807
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
807
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

1.1K
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.1K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.3K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.3K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

1.9K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.9K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.7K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and therapeutic yield of 72h stool collection combined with bile acid quantification: a retrospective analysis.

Acta gastro-enterologica Belgica·2025
Same author

Navigating the Maze of Functional Dyspepsia: Emergence of a New Entity, Postprandial Epigastric Pain Syndrome.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Esophageal Lichen Planus: a Narrative Review of the Literature.

Acta gastro-enterologica Belgica·2025
Same author

Belgian consensus on the management of patients with functional dyspepsia.

Acta gastro-enterologica Belgica·2025
Same author

Recommendations for the diagnosis and management of patients with chronic idiopathic diarrhea: Belgian multidisciplinary expert discussion based on a modified Delphi method.

Acta gastro-enterologica Belgica·2025
Same author

Functional Dyspepsia and Its Subgroups: Prevalence and Impact in the Rome IV Global Epidemiology Study.

Alimentary pharmacology & therapeutics·2025
Same journal

Trembling technique for improving colonic adenoma detection rate by enhancing mucosal exposure during withdrawal: A prospective, non-randomized single center study.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Consensus recommendations for the management of H. pylori in Egypt: 2026 report.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Pancreatitis in Familial Dysautonomia Patients.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Treatment outcomes with empirical Clarithromycin-based triple therapy for Helicobacter pylori in Zambia, sub-Saharan Africa.

Digestive diseases (Basel, Switzerland)·2026
Same journal

Endoscopic submucosal dissection-associated bacteremia: proper antibiotic management.

Digestive diseases (Basel, Switzerland)·2026
Same journal

The investigation and treatment of Helicobacter pylori for the prevention of gastric cancer: A narrative review and assessment of management approaches.

Digestive diseases (Basel, Switzerland)·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.3K

Therapeutic options for functional dyspepsia.

H Vanheel1, J Tack

  • 1Translational Research Center for Gastrointestinal Disorders, University of Leuven, Leuven, Belgium.

Digestive Diseases (Basel, Switzerland)
|April 16, 2014
PubMed
Summary
This summary is machine-generated.

Functional dyspepsia (FD) involves chronic gut symptoms without other causes. Treatments range from lifestyle changes to medications like proton pump inhibitors and prokinetics, with emerging therapies showing promise.

More Related Videos

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.3K

Related Experiment Videos

Last Updated: May 1, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.3K
Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

1.1K
Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation
04:04

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

1.3K

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Functional dyspepsia (FD) is characterized by chronic gastroduodenal symptoms.
  • It is diagnosed when organic or systemic diseases are excluded via upper endoscopy.
  • Rome III criteria classify FD into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS).

Purpose of the Study:

  • To review current and emerging therapeutic strategies for functional dyspepsia.
  • To outline treatment approaches based on FD subtypes and symptom severity.

Main Methods:

  • Literature review of pharmacotherapy and emerging treatments for FD.
  • Analysis of treatment guidelines and clinical trial data.

Main Results:

  • Mild FD symptoms may resolve with lifestyle adjustments.
  • Pharmacotherapy includes proton pump inhibitors (PPIs) for EPS, prokinetics for PDS, and psychotropic agents for refractory cases.
  • Helicobacter pylori eradication is recommended if present, though its impact on symptoms is variable.

Conclusions:

  • Proton pump inhibitors are first-line for EPS, while prokinetics are indicated for PDS.
  • Tricyclic antidepressants can manage refractory symptoms, particularly in EPS.
  • Novel agents like acotiamide, 5-HT(1A) agonists, and mirtazapine represent emerging therapeutic options for specific FD presentations.